Immunotherapy plus chemotherapy before surgery for advanced throat cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery, to shrink the cancer and improve outcomes for patients with advanced hypopharyngeal cancer. It may help make surgery more effective and reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You should be in fairly good health, able to do light work (ECOG 0-1).
- Your cancer must be removable with surgery, and you agree to have surgery.
- You must have hypopharyngeal cancer at a locally advanced stage (not spread to distant parts).
- You have not had any prior cancer treatment (like chemo, radiation, or immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy combined with an immunotherapy drug (finotonlimab) before surgery for locally advanced hypopharyngeal cancer. It aims to shrink the tumor enough to improve surgery outcomes.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy before surgery improves outcomes for people with advanced laryngeal or hypopharyngeal cancer. The treatment is given before your planned total laryngectomy, and the goal is to shrink the tumor and potentially improve long-term results.
This trial tests whether giving a combination of an immunotherapy drug (PD-1 inhibitor) and chemotherapy before surgery can help treat advanced throat cancer. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests whether adding immunotherapy before surgery, followed by either radiation or organ-preserving surgery, can improve outcomes for people with locally advanced laryngeal or hypopharyngeal cancer. It may help avoid complete removal of the voice box.
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Locally Advanced Hypopharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.